NO20053490L - Methods for prediciting therapeutic response to agents acting on the growth hormone receptor - Google Patents

Methods for prediciting therapeutic response to agents acting on the growth hormone receptor

Info

Publication number
NO20053490L
NO20053490L NO20053490A NO20053490A NO20053490L NO 20053490 L NO20053490 L NO 20053490L NO 20053490 A NO20053490 A NO 20053490A NO 20053490 A NO20053490 A NO 20053490A NO 20053490 L NO20053490 L NO 20053490L
Authority
NO
Norway
Prior art keywords
growth hormone
hormone receptor
methods
therapeutic response
agents acting
Prior art date
Application number
NO20053490A
Other languages
English (en)
Other versions
NO20053490D0 (no
Inventor
Pierre Bougneres
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of NO20053490D0 publication Critical patent/NO20053490D0/no
Publication of NO20053490L publication Critical patent/NO20053490L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)

Abstract

Fremgangsmåter forå produsere et individs respons på et middel som er i stand til å binde til et veksthormonreseptor (GHR) protein som omfatter å bestemme nærværet eller fraværet av et allel av (GHR) genet i individet, hvori allelet er koordinert med sannsynligheten for en øket eller redusert positiv respons på middelet, for derved å identifisere individet til å ha en øket eller redusert sannsynlighet for å respondere på behandlingen med middelet.
NO20053490A 2002-12-19 2005-07-18 Methods for prediciting therapeutic response to agents acting on the growth hormone receptor NO20053490L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43486102P 2002-12-19 2002-12-19
PCT/IB2003/005111 WO2004056864A1 (en) 2002-12-19 2003-11-10 Methods for predicting therapeutic response to agents acting on the growth hormone receptor

Publications (2)

Publication Number Publication Date
NO20053490D0 NO20053490D0 (no) 2005-07-18
NO20053490L true NO20053490L (no) 2005-09-16

Family

ID=23725994

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053490A NO20053490L (no) 2002-12-19 2005-07-18 Methods for prediciting therapeutic response to agents acting on the growth hormone receptor

Country Status (12)

Country Link
US (1) US20040180358A1 (no)
EP (1) EP1572738A1 (no)
JP (1) JP2006525785A (no)
KR (1) KR20050085855A (no)
CN (1) CN1747968A (no)
AU (1) AU2003278503A1 (no)
CA (1) CA2510045A1 (no)
HR (1) HRP20050563A2 (no)
NO (1) NO20053490L (no)
RU (1) RU2005122665A (no)
SE (1) SE0300959D0 (no)
WO (1) WO2004056864A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1766067A1 (en) * 2004-07-08 2007-03-28 Pharmacia & Upjohn Company LLC Methods for predicting therapeutic response to agents acting on the growth hormone receptor
GB0600122D0 (en) * 2006-01-05 2006-02-15 Univ Cardiff Mutation in the growth hormone receptor
WO2008109357A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
SG10201704777RA (en) * 2009-06-08 2017-07-28 Amunix Operating Inc Growth hormone polypeptides and methods of making and using same
MX353186B (es) 2009-09-03 2018-01-05 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
US20150133383A1 (en) * 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN103014007A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼α-乳白蛋白基因、重组蛋白及其克隆方法
CN103014005A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼a-fabp蛋白基因、重组蛋白及其克隆方法
CN103014008A (zh) * 2012-11-22 2013-04-03 新疆旺源驼奶实业有限公司 双峰驼ghr蛋白基因、重组蛋白及其克隆方法
CN112322657B (zh) * 2020-11-12 2023-04-25 浙江新码生物医药有限公司 一种人生长激素的体外活性检测方法
CA3222510A1 (en) 2021-06-18 2022-12-22 Peptidream Inc. Ghr-binding pending peptide and composition comprising same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
AU723494B2 (en) * 1996-02-13 2000-08-31 Jcr Pharmaceuticals Co., Ltd. Mutant human growth hormones and their uses
US6080911A (en) * 1997-04-15 2000-06-27 Ohio University Mice models of growth hormone insensitivity

Also Published As

Publication number Publication date
HRP20050563A2 (en) 2005-12-31
AU2003278503A1 (en) 2004-07-14
NO20053490D0 (no) 2005-07-18
KR20050085855A (ko) 2005-08-29
CN1747968A (zh) 2006-03-15
JP2006525785A (ja) 2006-11-16
WO2004056864A1 (en) 2004-07-08
CA2510045A1 (en) 2004-07-08
SE0300959D0 (sv) 2003-04-02
EP1572738A1 (en) 2005-09-14
RU2005122665A (ru) 2006-01-20
US20040180358A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
NO20053490L (no) Methods for prediciting therapeutic response to agents acting on the growth hormone receptor
Cinnioğlu et al. Excavating Y-chromosome haplotype strata in Anatolia
Fischer et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection
CA2735578C (en) Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
Abi Habib et al. 11p15 ICR1 partial deletions associated with IGF2/H19 DMR hypomethylation and Silver–Russell syndrome
NO20050935L (no) BMP-2 ostrogen-responsivt element og fremgangsmater for anvendelse av samme
IL144703A0 (en) Methods and reagents for treating glucose metabolic disorders
PL372107A1 (en) Over-expression of extremozyme genes in pseudomonads and closely related bacteria
BRPI0508347A (pt) sistema enfileirado para permitir aos usuários participarem de campanha usando mensagens sms e método de operar gerenciador de campanha
ATE446385T1 (de) Polymorphismen im nod2/card15 gen
Ravn et al. Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population
Xu et al. Association analysis of the MHC in lupus nephritis
Arakawa et al. ERAP1 controls the autoimmune response against melanocytes in psoriasis by generating the melanocyte autoantigen and regulating its amount for HLA-C* 06: 02 presentation
Pescucci et al. Chromosome 2 deletion encompassing the MAP2 gene in a patient with autism and Rett‐like features
Fischer et al. Decrease of interleukin-2 secretion is a new independent prognostic factor associated with poor survival in patients with small-cell lung cancer
NZ514347A (en) Polynucleotide sequencing detecting the interaction between the polynucleotide and a helicase / primase enzyme by measuring radiation
Matarazzo et al. Natural breaking of the maternal silence at the mouse and human imprinted Prader-Willi locus: A whisper with functional consequences
EP1535993A4 (en) METHOD FOR TRANSFERRING A BIOMOLECULE USING A VIRAL ENVELOPE AND COMPOSITION AND SYSTEM THEREOF
Fan et al. The impact of ANxA6 gene polymorphism on the efficacy of methotrexate treatment in psoriasis patients
Lee et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction and related risk factors
Nam et al. Calpain-10 and adiponectin gene polymorphisms in Korean type 2 diabetes patients
Xue et al. Gene expression changes in retinal Müller (glial) cells exposed to elevated pressure
Demily et al. ZDHHC8 single nucleotide polymorphism rs175174 is not associated with psychiatric features of the 22q11 deletion syndrome or schizophrenia
Jamsai et al. Genetic variants in the human glucocorticoid‐induced leucine zipper (GILZ) gene in fertile and infertile men
WO2004039312A3 (en) Optineurin and glaucoma

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application